CoChat

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial

Open access
Kuerer, Henry M, Smith, Benjamin D, Krishnamurthy, Savitri, Yang, Wei T, Valero, Vicente, Shen, Yu, Lin, Heather, Lucci, Anthony, Boughey, Judy C, White, Richard L, Diego, Emilia J, Rauch, Gaiane M, Moseley, Tanya W, van la Parra, Raquel FD, Adrada, Beatriz E, Leung, Jessica WT, Sun, Susie X, Teshome, Mediget, Miggins, Makesha V, Hunt, Kelly K, DeSnyder, Sarah M, Ehlers, Richard A, Hwang, Rosa F, Colen, Jessica S, Arribas,, Elsa, Samiian, Laila, Lesnikoski, Beth-Ann, Piotrowski, Mathew, Bedrosian, Isabelle, Chong, Clayton, Refinetti, Ana P, Huang, Monica, Candelaria, Rosalind P, Loveland-Jones, Catherine, Mitchell, Melissa P, Shaitelman, Simona F · 2022 · The Lancet Oncology
Cited by 165

The DOI matches its Crossref record.

Abstract

BACKGROUND Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and HER2-positive breast cancer yields a pathological complete response in approximately 60% of patients. A pathological complete response to NST predicts an excellent prognosis and can be accurately determined by percutaneous image-guided vacuum-assisted core biopsy (VACB). We evaluated radiotherapy alone, without breast surgery, in patients with early-stage triple-negative breast cancer or HER2-positive breast cancer treated with NST who had an image-guided VACB-determined pathological complete response. METHODS This multicentre, single-arm, phase 2 trial was done in seven centres in the USA. Women aged 40 years or older who were not pregnant with unicentric cT1-2N0-1M0 triple-negative breast cancer or HER2-positive breast cancer and a residual breast lesion less than 2 cm on imaging after clinically standard NST were eligible for inclusion. Patients had one biopsy (minimum of 12 cores) obtained by 9G image-guided VACB of the tumour bed. If no invasive or in-situ disease was identified, breast surgery was omitted, and patients underwent standard whole-breast radiotherapy (40 Gy in 15 fractions or 50 Gy in 25 fractions) plus a boost (14 Gy in seven fractions). The primary outcome was the biopsy-confirmed ipsilateral breast tumour recurrence rate determined using the Kaplan-Meier method assessed in the per-protocol population. Safety was assessed in all patients who received VACB. This study has completed accrual and is registered with ClinicalTrials.gov, NCT02945579. FINDINGS Between March 6, 2017, and Nov 9, 2021, 58 patients consented to participate; however, four (7%) did not meet final inclusion criteria and four (7%) withdrew consent. 50 patients were enrolled and underwent VACB following NST. The median age of the enrolled patients was 62 years (IQR 55-77); 21 (42%) patients had triple-negative breast cancer and 29 (58%) had HER2-positive breast cancer. VACB identified a pathological complete response in 31 patients (62% [95% CI 47·2-75·4). At a median follow-up of 26·4 months (IQR 15·2-39·6), no ipsilateral breast tumour recurrences occurred in these 31 patients. No serious biopsy-related adverse events or treatment-related deaths occurred. INTERPRETATION Eliminating breast surgery in highly selected patients with an image-guided VACB-determined pathological complete response following NST is feasible with promising early results; however, additional prospective clinical trials evaluating this approach are needed. FUNDING US National Cancer Institute (National Institutes of Health).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(22)00613-1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Kuerer, H. M., Smith, B. D., Krishnamurthy, S., Yang, W. T., Valero, V., Shen, Y., Lin, H., Lucci, A., Boughey, J. C., White, R. L., Diego, E. J., Rauch, G. M., Moseley, T. W., van la Parra, R. F., Adrada, B. E., Leung, J. W., Sun, S. X., Teshome, M., Miggins, M. V., Hunt, K. K., DeSnyder, S. M., Ehlers, R. A., Hwang, R. F., Colen, J. S., Arribas, Samiian, L., Lesnikoski, B.-A., Piotrowski, M., Bedrosian, I., Chong, C., Refinetti, A. P., Huang, M., Candelaria, R. P., Loveland-Jones, C., Mitchell, M. P., & Shaitelman, S. F.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-12
Volume
23
Issue
12
Pages
1517-1524
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4307399943
Cited by
165
References
0
FWCI
11.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00613-1
The paper
Kuerer, H. M., Smith, B. D., Krishnamurthy, S., Yang, W. T., Valero, V., Shen, Y., Lin, H., Lucci, A., Boughey, J. C., White, R. L., Diego, E. J., Rauch, G. M., Moseley, T. W., van la Parra, R. F., Adrada, B. E., Leung, J. W., Sun, S. X., Teshome, M., Miggins, M. V., . . . Shaitelman, S. F. (2022). Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00613-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.